Article
Ivosidenib in acute myeloid leukemia.
Expert opinion on pharmacotherapy - 1 Jan 2000
Bruzzese Antonella, Labanca Caterina, Martino Enrica Antonia, Mendicino Francesco, Lucia Eugenio, Olivito Virginia, Neri Antonino, Imovilli Annalisa, Morabito Fortunato, Vigna Ernesto, Gentile Massimo
Abstract excerpt
INTRODUCTION: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 (FLT3) inhibitors such as midostaurin and...
Topics
Join the communities discussing this publication.